Table 1.

(Continued)

Jadad
score
Topical or (RCT) or
ingested Level of
Disease Curcumin-containing curcumin Study design Number of Control or Major outcome Study Evidence*
assessed Study intervention product Dosage and duration subjects placebo measures Major results limitations (non-RCT)

Atopic Rawal Herbavate® Topical 5% 4-weeks, 150 None 1. Change in 1. Statistically 1. Open label IIB
dermatitis et al., 2009 cream (herbal Curcuma open-label symptom score significant non-comparative
(eczema) extracts of longa non-comparative at 4 weeks improvement in design.
Curcuma longa, trial compared with symptom score for
Calotropic baseline. all symptoms

Copyright © 2016 John Wiley & Sons, Ltd.

gigantean, assessed with
Pongomia p < 0.001.
glabra,
and Solanum
xanthocarpum)
2. Weekly Erythema: 29.7% 2. No control
symptom score decrease group
assessment
(erythema,
scaling,
thickening,
itching)
3. Side effects Scaling: 27.9% 3. High dropout
decrease rate of 20%,
A. R. VAUGHN ET AL.

which may be due

to poor follow-up.
Thickening: 34.66%
decrease
Itching: 31.73%
decrease
2. Only five subjects
reported side
effects
Facial Sommerfeld, Tricutan® Topical 0.1% Randomized, 28 Placebo gel 1. Skin 1. Significantly 1. Unable to 5
photoaging 2007 gel – herbal tetrahydrocurcumin placebo-controlled, without firmness and decreased propagation isolate the effects
extract double-blind, Tricutan® elasticity speed indicating of turmeric.
combination split-face study for measured using improved skin
(rosemary, 4 weeks. Reviscometer. firmness. RRTM in
gotu kola, and (RRTM) Tricutan group
turmeric) along decreased from
with 184 ± 61 to 164 ± 64,
dimethylaminoethanol

Phytother. Res. (2016)

(Continues)
 Table 1. (Continued)

Jadad
score
Topical or (RCT) or
ingested Level of
Disease Curcumin-containing curcumin Study design Number of Control or Major outcome Study Evidence*
assessed Study intervention product Dosage and duration subjects placebo measures Major results limitations (non-RCT)

improvement in
curcumin group
versus control.
Pruritus – multiple Chatterjee ‘Itch cream’ containing Topical 16% turmeric Prospective, 64 Moisturex cream 1. Pruritus 1. Both the treatment 1. This study IB
etiologies (atopic et al., 2005 turmeric 16%, saffron unicentric, open, (urea 10%, lactic severity using group (itch cream) examined a broad

Copyright © 2016 John Wiley & Sons, Ltd.

dermatitis, senile 0.025%, sandalwood randomized, acid 10%, subjective and the control range of pruritic
pruritis, ichthyosis) 8%, vetiver 0.5%, lata controlled propylene glycol scale (0–3): (Moisturex) had skin diseases,
kasturi 0.1%, mehendi study 10%, paraffin 0 = no pruritus, statistically which may not be
3%, tulasi 3%, 10%, cream base) 1 = mild, no significant comparable
yasatimadhu 0.5%, impairment of improvement in all in assessing
turmeric oil 0.1%, daily life, parameters (subjective efficacy of the
surasar 0.5%, and 2 = moderate, pruritus severity, treatment.
sarna bhasma impaired daily clinical assessment,
0.00032%. life, 3 = severe, and well-being).
sleepless nights. However, there was
no statistically
significant difference
between the
treatment and
control groups.
2. Clinical Group A (itch 2. Unable to
Composite cream): isolate the effects
assessment of 2.32 ± 0.69 to of Turmeric in the
keratinization, 1.40 ± 0.91, “Itch cream.”
EFFECTS OF Curcuma longa ON SKIN HEALTH

excoriation, p < 0.005

fissuring (0–3):
0 = no features,
1 = mild,
2 = moderate,
3 = severe.
3. Patient Global Group B
Assessment of (Moisturex):
Well-Being 2.52 ± 0.51 to
(0–3): 1.48 ± 1.03,
0 = complete p < 0.005
relief,
1 = significant

Phytother. Res. (2016)

(Continues)
 Table 1. (Continued)

Jadad
score
Topical or (RCT) or
ingested Level of
Disease Curcumin-containing curcumin Study design Number of Control or Major outcome Study Evidence*
assessed Study intervention product Dosage and duration subjects placebo measures Major results limitations (non-RCT)

resolution after
3–8 weeks.
The curcumin-treated
group had
significantly lower

Copyright © 2016 John Wiley & Sons, Ltd.

PhK activity than the
calcipotriol-treated
group.
Psoriasis Kurd Curcuminoid C3 Ingested 4275 mg 16-weeks, phase II, 8 None 1. Physicians 1. Responder rate 1. Small sample IIB
et al., 2008 complex capsules – curcuminoids/day open-label Global based on at least a size
4.5 g/day two-stage Assessment ‘good’ PGA: 16.7%
clinical trial for 16 Score (PGA) at response rate with
weeks 12 weeks: 95% confidence
‘Responder’ interval (2%, 48%).
= rating of
good (50–74%
improvement),
excellent
(75–99%
improvement),
or cleared
(100%
improvement).
2. PASI 2. PASI: the two 2. Lack of
EFFECTS OF Curcuma longa ON SKIN HEALTH

responders achieved placebo group

a score of 75 at week
16.
3. Safety end 3. Mild GI upset or
points hot flashes in
18 adverse events.
Radiodermatitis Palatty Turmeric- and sandal Topical 16% turmeric 7-weeks, 50 Baby oil (mineral 1. Clinically 1. Turmeric cream 1. Not IIA
in head and et al., 2014 wood oil cream investigator-blinded oil, parfum) assessed (VTC) significantly double-blinded.
neck cancer (Vicco® turmeric random sampling dermatitis reduced Grade 3
patients cream VTC) study grading dermatitis.
undergoing (RTOG)
radiation
2. Side effects

Phytother. Res. (2016)

(Continues)